Skip to main content

Table 3 Comparison of the frequency of peripheral sensory neuropathy between present study and phase 3 trials

From: Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan

Regimen

Grade

Present study

Phase 3 trials

CapeOX

All Grade

54.4 %

78.0 %a

≥ Grade 3

1.80 %

11.0 %a

mFOLFOX6

All Grade

90.0 %

92.0 %b

≥ Grade 3

40.0 %

12.5 %b

  1. Grade of neuropathy was evaluated according to the Common Terminology Criteria for Adverse Events version 3.0.
  2. aData from reference [8]; bResult of FOLFOX4 [9]. Effectiveness and safety of mFOLFOX6 were comparable to those of FOLFOX4 [10].